Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B

Hao WANG; Shan SHAN; Hong YOU; Xiaoyuan XU; Lai WEI; Jinlin HOU; Hui ZHUANG; Yuanyuan KONG; Jidong JIA; China Registry of Hepatitis B (CR-HepB) Group

doi:10.3969/j.issn.1001-5256.2022.06.011

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1269-1274

PDF( 2465 KB)

Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2022.06.011

Hao WANG^1a,
Shan SHAN^1b,
Hong YOU^1b,
Xiaoyuan XU²,
Lai WEI³,
Jinlin HOU⁴,
Hui ZHUANG⁵,
Yuanyuan KONG^{1a
,
,
,},
Jidong JIA^{1b
,
,
,},
China Registry of Hepatitis B (CR-HepB) Group

1a.
Department of Clinical Epidemiology and Evidence-based Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
1b.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2.
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
3.
Department of Hepatology, Beijing Tsinghua Changgung Hospital, Beijing 100044, China
4.
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
5.
Department of Microbiology and Parasitology, Peking University Health Science Center, Beijing 100191, China

Research funding:

Beijing Municipal Science and Technology Commission (Z191100007619037);

Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (XXX0104);

Beijing Municipal Health Commission (2022-3-018);

Capital Medical University (PYZ21051)

More Information

Corresponding author: KONG Yuanyuan, kongyy@ccmu.edu.cn (ORCID:0000-0002-2586-1443); JIA Jidong, jia_jd@ccmu.edu.cn (ORCID:0000-0002-4673-8890)
Received Date: 2022-04-08
Accepted Date: 2022-05-12
Published Date: 2022-06-20

Abstract

Abstract

Objective To investigate the impact of the change in anti-hepatitis B virus (HBV) therapy indication on treatment rate and the features of the population requiring treatment. Methods The treatment-naïve patients with chronic hepatitis B (CHB) in the China Registry of Hepatitis B (CR-HepB) database were selected as subjects, and related demographic, virological, hematological, and biochemical data were collected. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. Results A total of 3640 treatment-naïve CHB patients were included in this study, among whom 64.4% were male, 68.7% had an age of 30-59 years, and 46.8% had an indeterminate clinical stage. According to the 2015 and 2019 editions of Guidelines for the prevention and treatment of chronic hepatitis B and the 2022 edition of expert consensus, the number of patients who had the indication for antiviral therapy was 625(17.2%), 1333(36.6%), and 2890(79.4%), respectively. The number of patients requiring treatment was increased by 1557 according to the 2022 edition of expert consensus, among whom 1424(91.5%) met the treatment threshold of alanine aminotransferase (ALT) > 30 U/L for male patients or ALT > 19 U/L for female patients. The additional patients requiring treatment according to the 2022 edition of expert consensus had significantly higher levels of ALT and HBV DNA and significantly lower scores of APRI and FIB-4 than the additional patients requiring treatment according to the 2019 edition of Guidelines (all P < 0.05). Conclusion The expansion of antiviral therapy indications for CHB may significantly increase the proportion of CHB patients receiving antiviral treatment and help mild CHB patients at the risk of disease progression to receive timely treatment and achieve the improvement in long-term prognosis.
- Hepatitis B, Chronic,
- Antiviral Agents,
- Indication

FullText(HTML)

References(20)

References

[1]	YUEN MF, CHEN DS, DUSHEIKO GM, et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers, 2018, 4: 18035. DOI: 10.1038/nrdp.2018.35.
[2]	LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[3]	HOU JL, ZHAO W, LEE C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 457-467. e21. DOI: 10.1016/j.cgh.2019.07.010.
[4]	SINN DH, KIM SE, KIM BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019, 26(12): 1465-1472. DOI: 10.1111/jvh.13185.
[5]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[6]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[7]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[8]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[9]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[10]	Chinese Society of Hepatology, Chinese Medical Association. Expert opinion on expanding anti-HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn50113-20220209-00060. 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn50113-20220209-00060.
[11]	SHAN S, YOU H, NIU J, et al. Baseline characteristics and treatment patterns of the patients recruited to the china registry of hepatitis B[J]. J Clin Transl Hepatol, 2019, 7(4): 322-328. DOI: 10.14218/JCTH.2019.00052.
[12]	KONG YY, WEI W, SHAN S, et al. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis[J]. Chin Hepatol, 2020, 25(2): 123-127. DOI: 10.14000/j.cnki.issn.1008-1704.2020.02.011. 孔媛媛, 魏巍, 单姗, 等. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127. DOI: 10.14000/j.cnki.issn.1008-1704.2020.02.011.
[13]	SHAN S, WEI W, KONG Y, et al. China registry of hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B[J]. Scand J Public Health, 2020, 48(2): 233-239. DOI: 10.1177/1403494818772188.
[14]	XIAO G, YANG J, YAN L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis[J]. Hepatology, 2015, 61(1): 292-302. DOI: 10.1002/hep.27382.
[15]	LEE MH, YANG HI, LIU J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles[J]. Hepatology, 2013, 58(2): 546-554. DOI: 10.1002/hep.26385.
[16]	DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.
[17]	LI M, KONG YY, WU SS, et al. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China[J]. J Dig Dis, 2019, 20(9): 467-475. DOI: 10.1111/1751-2980.12794.
[18]	TORDRUP D, HUTIN Y, STENBERG K, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30[J]. The Lancet Global Health, 2019, 7(9): e1180-e1188. DOI: 10.1016/S2214-109X(19)30272-4.
[19]	NAYAGAM S, CHAN P, ZHAO K, et al. Investment case for a comprehensive package of interventions against hepatitis B in China: Applied modeling to help national strategy planning[J]. Clin Infect Dis, 2021, 72(5): 743-752. DOI: 10.1093/cid/ciaa134.
[20]	JIA JD, HOU JL, WEI L, et al. Highlights of the guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chin J Hepatol, 2020, 28 (1): 21-23. DOI: 10.376/cma.j.issn.1007-3418.2020.01.006. 贾继东, 侯金林, 魏来, 等. 《慢性乙型肝炎防治指南(2019年版)》新亮点[J]. 中华肝脏病杂志, 2020, 28 (1):21-23. DOI:10.3760/cma.j.issn.1007-3418.2020.01.006.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (821) PDF downloads(157)

Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2022.06.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2022.06.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content